Keyword: Atara Biotherapeutics
In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.
It’s that time again, when companies come together to shout about (or try to quietly hide) their cancer data at the ASCO annual meeting.
Novartis' Kymriah head jumps ship to Atara; Gilead's new chief steals BMS executive; and Sanofi hires ex-Genentech and Atara exec to lead development.
Berger, a cancer specialist, ended his brief stint in biotech earlier this month to return to Big Pharma R&D at Sanofi.
Novartis has lost its head of oncology Pascal Touchon as he steps up to become the CEO and president of California biotech Atara.
Celgene's shake-ups continue with new CFO, Zai Lab grabs top AZ exec, Axovant brings on Spark co-founder as CTO, and Gilead promotes its top dealmaker.
Atara hires ex-Genentech SVP to lead R&D, Semma names former Novartis CAR-T developer as CEO, and GSK's CFO heads for the exit.
Berger Atara joins after seven years at Roche’s Genentech, during which time he had a hand in the approval of drugs including Tecentriq.
Achillion appoints Joseph Truitt after CEO steps down; Lilly hires Leena Gandhi to lead new I-O team; and C4 promotes Andrew Phillips to CEO.
The series C tees up Scholar Rock to find out whether its myostatin blocker can best one-time rivals from companies including Novartis.
